Index DJIA, S&P 500
P/E 17.50
EPS (ttm) 9.00
Insider Own 0.13%
Shs Outstand 2.41B
Perf Week 5.90%
Market Cap 379.48B
Forward P/E 14.24
EPS next Y 11.06
Insider Trans -0.62%
Shs Float 2.41B
Perf Month -3.39%
Income 21.81B
PEG 3.09
EPS next Q 2.67
Inst Own 73.05%
Short Float 0.80%
Perf Quarter 6.56%
Sales 89.33B
P/S 4.25
EPS this Y 5.99%
Inst Trans 0.72%
Short Ratio 1.88
Perf Half Y -4.04%
Book/sh 29.70
P/B 5.30
EPS next Y 4.53%
ROA 8.09%
Short Interest 19.15M
Perf Year 9.01%
Cash/sh 10.18
P/C 15.48
EPS next 5Y 5.66%
ROE 20.06%
52W Range 140.68 - 169.99
Perf YTD 8.89%
Dividend Est. 4.94 (3.14%)
P/FCF 19.13
EPS past 5Y 0.55%
ROI 21.10%
52W High -7.37%
Beta 0.43
Dividend TTM 4.96 (3.15%)
Quick Ratio 0.86
Sales past 5Y 2.03%
Gross Margin 75.56%
52W Low 11.93%
ATR (14) 4.43
Dividend Ex-Date Feb 18, 2025
Current Ratio 1.11
EPS Y/Y TTM 3.69%
Oper. Margin 23.72%
RSI (14) 51.19
Volatility 2.71% 2.74%
Employees 138100
Debt/Eq 0.53
Sales Y/Y TTM -0.37%
Profit Margin 24.42%
Recom 2.17
Target Price 170.61
Option/Short Yes / Yes
LT Debt/Eq 0.45
EPS Q/Q 238.80%
Payout 84.80%
Rel Volume 1.08
Prev Close 153.91
Sales Surprise 1.55%
EPS Surprise 7.33%
Sales Q/Q 2.39%
Earnings Apr 15 BMO
Avg Volume 10.19M
Price 157.47
SMA20 0.45%
SMA50 -1.37%
SMA200 0.46%
Trades
Volume 10,971,376
Change 2.31%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-10-24 Resumed
BofA Securities
Neutral
$166
Nov-15-24 Initiated
Wolfe Research
Outperform
$190
Jul-23-24 Downgrade
Daiwa Securities
Outperform → Neutral
$160 → $150
May-30-24 Resumed
Goldman
Neutral
$160
Apr-18-24 Upgrade
HSBC Securities
Hold → Buy
$170
Dec-13-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$170 → $163
Dec-01-23 Upgrade
UBS
Neutral → Buy
$167 → $180
Oct-05-23 Initiated
RBC Capital Mkts
Outperform
$178
Sep-06-23 Initiated
HSBC Securities
Hold
$175
May-30-23 Resumed
Citigroup
Buy
$185
Mar-29-23 Initiated
UBS
Neutral
$164
Mar-01-23 Initiated
Guggenheim
Neutral
$161
Nov-18-22 Initiated
Credit Suisse
Neutral
$170
Oct-18-22 Initiated
Barclays
Equal Weight
$175
Oct-14-22 Reiterated
BofA Securities
Neutral
$185 → $178
Jun-22-22 Initiated
Daiwa Securities
Outperform
May-23-22 Resumed
SVB Leerink
Outperform
$200
Apr-06-22 Resumed
Morgan Stanley
Equal-Weight
$173
Mar-16-22 Downgrade
Bernstein
Outperform → Mkt Perform
$180 → $183
Mar-02-22 Resumed
BofA Securities
Neutral
$185
Show Previous Ratings
Apr-19-25 09:01PM
11:42AM
10:30AM
05:30AM
01:25AM
03:08PM
Loading…
Apr-18-25 03:08PM
07:00AM
(The Wall Street Journal)
Apr-17-25 10:01PM
10:51AM
09:15AM
08:10AM
08:05AM
08:03AM
07:05AM
06:20AM
04:51AM
Loading…
04:51AM
04:07AM
Apr-16-25 06:35PM
04:28PM
04:28PM
02:41PM
12:28PM
11:59AM
11:24AM
11:19AM
10:00AM
09:31AM
07:58AM
03:00AM
01:26AM
(Thomson Reuters StreetEvents)
10:15PM
Loading…
Apr-15-25 10:15PM
04:44PM
04:42PM
03:49PM
03:26PM
(The Wall Street Journal)
03:06PM
03:01PM
03:00PM
02:40PM
(Pharmaceutical Technology)
01:20PM
12:42PM
12:07PM
12:05PM
11:53AM
11:51AM
11:20AM
(Associated Press Finance)
11:15AM
11:14AM
11:04AM
(The Wall Street Journal)
11:04AM
10:54AM
10:53AM
10:51AM
10:43AM
10:42AM
(Investor's Business Daily)
10:19AM
09:47AM
09:30AM
09:09AM
08:57AM
08:55AM
08:49AM
(Investor's Business Daily)
08:49AM
(Investor's Business Daily)
08:44AM
08:08AM
07:54AM
07:52AM
07:52AM
07:35AM
07:22AM
07:14AM
06:35AM
06:32AM
06:29AM
(Associated Press Finance)
06:25AM
06:23AM
06:20AM
Apr-14-25 11:32PM
07:00PM
05:44PM
04:44PM
12:17PM
09:50AM
03:22AM
02:30AM
Apr-13-25 05:41PM
05:29PM
02:12PM
09:37AM
08:01AM
06:00AM
Apr-12-25 11:00AM
09:05AM
08:30AM
Apr-11-25 01:59PM
12:46PM
12:45PM
11:32AM
07:41AM
06:20AM
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Decker Robert J VP Corporate Controller Feb 25 '25 Option Exercise 101.87 6,999 712,988 28,000 Feb 26 06:42 PM Decker Robert J VP Corporate Controller Feb 25 '25 Sale 165.88 6,999 1,160,994 21,001 Feb 26 06:42 PM Decker Robert J Officer Feb 25 '25 Proposed Sale 165.88 6,999 1,161,010 Feb 25 03:05 PM Schmid Timothy EVP, WW Chair, MedTech Feb 14 '25 Option Exercise 0.00 2,806 0 17,904 Feb 18 09:46 PM Schmid Timothy EVP, WW Chair, MedTech Feb 15 '25 Option Exercise 0.00 1,029 0 15,501 Feb 18 09:33 PM Schmid Timothy EVP, WW Chair, MedTech Feb 14 '25 Option Exercise 0.00 1,765 0 15,111 Feb 18 09:33 PM Schmid Timothy EVP, WW Chair, MedTech Feb 13 '25 Option Exercise 0.00 499 0 13,539 Feb 18 09:33 PM Schmid Timothy EVP, WW Chair, MedTech Feb 18 '25 Sale 156.15 403 62,928 15,098 Feb 18 09:33 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Feb 15 '25 Option Exercise 0.00 607 0 91,037 Feb 18 09:16 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Feb 14 '25 Option Exercise 0.00 7,367 0 96,674 Feb 18 09:16 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Feb 13 '25 Option Exercise 0.00 651 0 89,603 Feb 18 09:16 PM Wolk Joseph J Exec VP, CFO Feb 15 '25 Option Exercise 0.00 1,971 0 6,113 Feb 18 09:13 PM Wolk Joseph J Exec VP, CFO Feb 14 '25 Option Exercise 0.00 19,330 0 20,661 Feb 18 09:13 PM Wolk Joseph J Exec VP, CFO Feb 13 '25 Option Exercise 0.00 1,779 0 1,779 Feb 18 09:13 PM REED JOHN C EVP, Innovative Medicine, R&D Feb 15 '25 Option Exercise 0.00 1,350 0 15,927 Feb 18 09:11 PM Taubert Jennifer L EVP, WWC. Innovative Medicine Feb 15 '25 Option Exercise 0.00 1,594 0 171,110 Feb 18 09:08 PM Taubert Jennifer L EVP, WWC. Innovative Medicine Feb 14 '25 Option Exercise 0.00 19,518 0 185,924 Feb 18 09:08 PM Taubert Jennifer L EVP, WWC. Innovative Medicine Feb 13 '25 Option Exercise 0.00 1,302 0 167,221 Feb 18 09:08 PM Swanson James D. EVP, CIO Feb 15 '25 Option Exercise 0.00 492 0 16,762 Feb 18 09:06 PM Swanson James D. EVP, CIO Feb 14 '25 Option Exercise 0.00 5,079 0 19,739 Feb 18 09:06 PM Swanson James D. EVP, CIO Feb 13 '25 Option Exercise 0.00 447 0 15,019 Feb 18 09:06 PM Mulholland Kristen EVP, Chief HR Officer Feb 15 '25 Option Exercise 0.00 419 0 13,095 Feb 18 09:05 PM Mulholland Kristen EVP, Chief HR Officer Feb 14 '25 Option Exercise 0.00 2,608 0 14,576 Feb 18 09:05 PM Mulholland Kristen EVP, Chief HR Officer Feb 13 '25 Option Exercise 0.00 411 0 12,100 Feb 18 09:05 PM Forminard Elizabeth Executive VP, General Counsel Feb 15 '25 Option Exercise 0.00 961 0 10,321 Feb 18 09:03 PM Forminard Elizabeth Executive VP, General Counsel Feb 14 '25 Option Exercise 0.00 2,203 0 11,366 Feb 18 09:03 PM Forminard Elizabeth Executive VP, General Counsel Feb 13 '25 Option Exercise 0.00 651 0 8,991 Feb 18 09:03 PM Duato Joaquin CEO and Chairman of the Board Feb 15 '25 Option Exercise 0.00 3,682 0 397,525 Feb 18 09:02 PM Duato Joaquin CEO and Chairman of the Board Feb 14 '25 Option Exercise 0.00 24,335 0 415,205 Feb 18 09:02 PM Duato Joaquin CEO and Chairman of the Board Feb 13 '25 Option Exercise 0.00 3,470 0 392,498 Feb 18 09:02 PM Decker Robert J VP Corporate Controller Feb 15 '25 Option Exercise 0.00 339 0 20,116 Feb 18 09:01 PM Decker Robert J VP Corporate Controller Feb 14 '25 Option Exercise 0.00 2,201 0 21,373 Feb 18 09:01 PM Decker Robert J VP Corporate Controller Feb 13 '25 Option Exercise 0.00 312 0 19,285 Feb 18 09:01 PM Broadhurst Vanessa EVP, Global Corp Affairs Feb 15 '25 Option Exercise 0.00 492 0 21,839 Feb 18 08:58 PM Broadhurst Vanessa EVP, Global Corp Affairs Feb 14 '25 Option Exercise 0.00 4,740 0 24,591 Feb 18 08:58 PM Broadhurst Vanessa EVP, Global Corp Affairs Feb 13 '25 Option Exercise 0.00 408 0 20,242 Feb 18 08:58 PM Duato Joaquin CEO and Chairman of the Board Feb 07 '25 Option Exercise 100.06 126,369 12,644,482 489,671 Feb 11 07:43 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Feb 07 '25 Option Exercise 100.06 32,762 3,278,166 115,028 Feb 11 07:42 PM Taubert Jennifer L EVP, WWC. Innovative Medicine Feb 07 '25 Option Exercise 100.06 58,504 5,853,910 213,355 Feb 11 07:41 PM Wolk Joseph J Exec VP, CFO Feb 07 '25 Option Exercise 100.06 13,015 1,302,281 13,015 Feb 11 07:40 PM Wolk Joseph J Exec VP, CFO Feb 07 '25 Sale 153.89 13,015 2,002,878 0 Feb 11 07:40 PM Wolk Joseph J Officer Feb 07 '25 Proposed Sale 153.89 13,015 2,002,924 Feb 07 01:27 PM WEINBERGER MARK A Director Dec 12 '24 Buy 147.22 1,000 147,220 1,000 Dec 12 05:27 PM Hait William Former Officer Dec 04 '24 Proposed Sale 149.90 25,742 3,858,598 Dec 04 01:25 PM Decker Robert J VP Corporate Controller Aug 30 '24 Option Exercise 100.06 5,635 563,838 24,608 Sep 03 04:48 PM Decker Robert J VP Corporate Controller Aug 30 '24 Sale 165.06 5,635 930,113 18,973 Sep 03 04:48 PM Decker Robert J Officer Aug 30 '24 Proposed Sale 165.06 5,635 930,113 Aug 30 03:51 PM Broadhurst Vanessa EVP, Global Corp Affairs Jul 08 '24 Option Exercise 0.00 9,809 0 24,852 Jul 09 05:48 PM REED JOHN C EVP, Innovative Medicine, R&D May 01 '24 Option Exercise 0.00 22,255 0 22,561 May 03 04:31 PM